Literature DB >> 9364254

Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.

G Lupoli1, C Di Carlo, V Nuzzo, G Vitale, D Russo, S Palomba, C Nappi.   

Abstract

Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9364254     DOI： 10.1007/BF03348007

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  19 in total

1.  Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women.

Authors:  W H Matta; R W Shaw; R Hesp; R Evans
Journal:  Clin Endocrinol (Oxf)       Date:  1988-07       Impact factor: 3.478

2.  The correlation of serum estrogens and androgens with bone density in the late postmenopause.

Authors:  S Deutsch; F Benjamin; V Seltzer; M Tafreshi; G Kocheril; A Frank
Journal:  Int J Gynaecol Obstet       Date:  1987-06       Impact factor: 3.561

Review 3.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

4.  Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea.

Authors:  C Di Carlo; Z Shoham; J MacDougall; A Patel; M L Hall; H S Jacobs
Journal:  Fertil Steril       Date:  1992-02       Impact factor: 7.329

5.  Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.

Authors:  E Carmina; A Janni; R A Lobo
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

6.  Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; P Morosini; R De Pirro
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

7.  Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.

Authors:  R Azziz; T M Ochoa; E L Bradley; H D Potter; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

8.  Evidence for alteration of the vitamin D-endocrine system in obese subjects.

Authors:  N H Bell; S Epstein; A Greene; J Shary; M J Oexmann; S Shaw
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.

Authors:  S Waibel-Treber; H W Minne; S H Scharla; T Bremen; R Ziegler; G Leyendecker
Journal:  Hum Reprod       Date:  1989-05       Impact factor: 6.918

Review 10.  The effect of obesity on postmenopausal bone loss and the risk of osteoporosis.

Authors:  C Ribot; F Trémollières; J M Pouillès
Journal:  Adv Nutr Res       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.